Literature DB >> 14969392

The signaling adapter protein DAP12 regulates multinucleation during osteoclast development.

Mary Beth Humphrey1, Kouetsu Ogasawara, Wei Yao, Steven C Spusta, Michael R Daws, Nancy E Lane, Lewis L Lanier, Mary C Nakamura.   

Abstract

UNLABELLED: Deficiency of the signaling adapter protein DAP12 is associated with bony abnormalities in both mice and humans. We identify specific DAP12-associated receptors expressed by osteoclasts and examine function of DAP12 in murine osteoclasts in vivo and in vitro. These data show a new role for DAP12 signaling in regulating formation of multinucleated osteoclasts.
INTRODUCTION: Osteoclasts are bone-resorbing cells derived from hematopoietic precursors in the myeloid lineage. In other myeloid cell types, the signaling adapter protein DAP12 transmits activating signals on ligation of a DAP12-associated receptor (DAR). The aim of this study was to clarify the role of DAP12 signaling during osteoclast development.
MATERIALS AND METHODS: Osteoclasts from DAP12 -/- or control mice were analyzed in vitro for morphology, function, and for osteoclast markers. DARs were identified in osteoclast cultures through reverse transcriptase-polymerase chain reaction (RT-PCR). Bone density of DAP12 -/- and control mice were analyzed by microcomputed tomography. DAP12 -/- osteoclasts were retrovirally reconstituted with DAP12. RAW264.7 cells were transfected with FLAG-tagged DAP12 or TREM2 and stimulated by anti-FLAG antibody during in vitro osteoclastogenesis.
RESULTS: C57BL/6 DAP12-deficient mice have higher bone mass than C57BL/6 wildtype controls. We verified the presence of DAP12 in pre-osteoclasts and osteoclasts derived from C57BL/6 or the pre-osteoclast line RAW 264.7 and identified the DARs expressed. DAP12 -/- osteoclasts developed in vitro with macrophage colony-stimulating factor (M-CSF) and RANKL formed only intensely TRACP+ mononuclear cells and failed to generate multinuclear osteoclasts. These mononuclear cells are functional osteoclast-like cells because, by RT-PCR, they express other osteoclast markers and generate resorption pits on dentine slices, although quantitative assessment of bone resorption shows decreased resorption by DAP12 -/- osteoclasts compared with C57BL/6 osteoclasts. Restoration of DAP12 expression by retroviral transduction of DAP12 -/- osteoclast precursors rescued in vitro osteoclast multinucleation. Direct stimulation of DAP12 expressed in RAW264.7 during in vitro osteoclastogenesis led to a marked increase in the number of TRACP+ multinucleated osteoclast-like cells formed.
CONCLUSION: Our studies indicate that stimulation of the DAP12 adapter protein plays a significant role in formation of multinuclear osteoclasts and that DAP12 and DARs likely participate in the regulation of bony remodeling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14969392     DOI: 10.1359/JBMR.0301234

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  45 in total

1.  Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12.

Authors:  Jessica A Hamerman; Nadia K Tchao; Clifford A Lowell; Lewis L Lanier
Journal:  Nat Immunol       Date:  2005-05-15       Impact factor: 25.606

2.  TREM2 and β-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis.

Authors:  Karel Otero; Masahiro Shinohara; Haibo Zhao; Marina Cella; Susan Gilfillan; Angela Colucci; Roberta Faccio; F Patrick Ross; Steve L Teitelbaum; Hiroshi Takayanagi; Marco Colonna
Journal:  J Immunol       Date:  2012-02-06       Impact factor: 5.422

3.  Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice.

Authors:  Wei Yao; Zhiqiang Cheng; Cheryl Busse; Aaron Pham; Mary C Nakamura; Nancy E Lane
Journal:  Arthritis Rheum       Date:  2008-06

Review 4.  RNA therapeutics targeting osteoclast-mediated excessive bone resorption.

Authors:  Yuwei Wang; David W Grainger
Journal:  Adv Drug Deliv Rev       Date:  2011-09-10       Impact factor: 15.470

Review 5.  The expanding roles of ITAM adapters FcRgamma and DAP12 in myeloid cells.

Authors:  Jessica A Hamerman; Minjian Ni; Justin R Killebrew; Ching-Liang Chu; Clifford A Lowell
Journal:  Immunol Rev       Date:  2009-11       Impact factor: 12.988

6.  The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase.

Authors:  Attila Mócsai; Mary Beth Humphrey; Jessica A G Van Ziffle; Yongmei Hu; Andrew Burghardt; Steven C Spusta; Sharmila Majumdar; Lewis L Lanier; Clifford A Lowell; Mary C Nakamura
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-08       Impact factor: 11.205

Review 7.  A Comprehensive Review of Immunoreceptor Regulation of Osteoclasts.

Authors:  Mary Beth Humphrey; Mary C Nakamura
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

8.  Myeloid DAP12-associating lectin (MDL)-1 regulates synovial inflammation and bone erosion associated with autoimmune arthritis.

Authors:  Barbara Joyce-Shaikh; Michael E Bigler; Cheng-Chi Chao; Erin E Murphy; Wendy M Blumenschein; Iannis E Adamopoulos; Paul G Heyworth; Svetlana Antonenko; Edward P Bowman; Terrill K McClanahan; Joseph H Phillips; Daniel J Cua
Journal:  J Exp Med       Date:  2010-03-08       Impact factor: 14.307

9.  Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone.

Authors:  L Endo-Munoz; A Cumming; S Sommerville; I Dickinson; N A Saunders
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

10.  CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis.

Authors:  Yahui Grace Chiu; Tianmeng Shao; Changyong Feng; Kofi A Mensah; Michael Thullen; Edward M Schwarz; Christopher T Ritchlin
Journal:  Arthritis Res Ther       Date:  2010-01-26       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.